Abstract
Edible plants are gaining importance as an integrative therapy for many chronic diseases, including cancer. We first reported that the edible wild plant Crithmum maritimum L. inhibits the growth of hepatocellular carcinoma (HCC) cells by exerting a multitarget action on cellular metabolism and bioenergetic profile. Here, we show that Crithmum maritimum ethyl acetate extract significantly increases the responsiveness of HCC cells to the chemotherapeutic drug sorafenib by reducing lactic acid fermentation and inducing a pro-hepatocyte biomarker profile. Our findings strengthen the role of Crithmum maritimum L. as a valuable nutraceutical tool to support pharmacological therapeutic interventions in HCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
All data presented in this study are available upon request.
References
Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod 83(3):770–803. https://doi.org/10.1021/acs.jnatprod.9b01285
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56(Suppl 1):S75-87. https://doi.org/10.1016/S0168-8278(12)60009-9
Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet. https://doi.org/10.1016/S0140-6736(18)30010-2
Gnocchi D, Cesari G, Calabrese GJ, Capone R, Sabba C, Mazzocca A (2020) Inhibition of hepatocellular carcinoma growth by ethyl acetate extracts of Apulian Brassica oleracea L. and Crithmum maritimum L. Plant Foods Hum Nutr 75 (1):33–40. https://doi.org/10.1007/s11130-019-00781-3
Gnocchi D, Del Coco L, Girelli CR, Castellaneta F, Cesari G, Sabba C, Fanizzi FP, Mazzocca A (2021) (1)H-NMR metabolomics reveals a multitarget action of Crithmum maritimum ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. Sci Rep 11(1):1259. https://doi.org/10.1038/s41598-020-78867-1
Gnocchi D, Sabba C, Mazzocca A (2022) The edible plant Crithmum maritimum shows nutraceutical properties by targeting energy metabolism in hepatic cancer. Plant Foods Hum Nutr 77(3):481–483. https://doi.org/10.1007/s11130-022-00986-z
Gnocchi D, Castellaneta F, Cesari G, Fiore G, Sabba C, Mazzocca A (2021) Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy. J Pharm Pharmacol. https://doi.org/10.1093/jpp/rgab070
Hong SM, Lee YK, Park I, Kwon SM, Min S, Yoon G (2019) Lactic acidosis caused by repressed lactate dehydrogenase subunit B expression down-regulates mitochondrial oxidative phosphorylation via the pyruvate dehydrogenase (PDH)-PDH kinase axis. J Biol Chem 294(19):7810–7820. https://doi.org/10.1074/jbc.RA118.006095
Nwosu ZC, Battello N, Rothley M, Pioronska W, Sitek B, Ebert MP, Hofmann U, Sleeman J, Wolfl S, Meyer C, Megger DA, Dooley S (2018) Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. J Exp Clin Cancer Res 37(1):211. https://doi.org/10.1186/s13046-018-0872-6
Tzonou A, Sparos L, Kalapothaki V, Zavitsanos X, Rebelakos A, Trichopoulos D (1990) Alpha 1-antitrypsin and survival in hepatocellular carcinoma. Br J Cancer 61(1):72–73. https://doi.org/10.1038/bjc.1990.16
Ohguchi S, Nakatsukasa H, Higashi T, Ashida K, Nouso K, Ishizaki M, Hino N, Kobayashi Y, Uematsu S, Tsuji T (1998) Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology 27(2):599–607. https://doi.org/10.1002/hep.510270239
Gnocchi D, Kurzyk A, Mintrone A, Lentini G, Sabba C, Mazzocca A (2022) Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. Biochimie. https://doi.org/10.1016/j.biochi.2022.07.016
Acknowledgements
We are grateful to Ms Loredana Angela Acquaro for her technical support.
Funding
This work was supported by Agenzia Regionale Strategica per la Salute ed il Sociale (ARESS) Puglia (Project "The Apulian Lifestyle" – Delibera di Giunta n. 556 (18/04/2017).
Author information
Authors and Affiliations
Contributions
D.G. performed the experiments and wrote the manuscript, C.S. revised the manuscript, A.M. conceived the article, wrote and revised the manuscript.
Corresponding author
Ethics declarations
Ethical Approval
Not applicable.
Consent to Participate
This article has been approved by all authors.
Consent for Publication
This manuscript has not been copyrighted or published elsewhere.
Conflict of Interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gnocchi, D., Sabbà, C. & Mazzocca, A. Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma. Plant Foods Hum Nutr 78, 230–232 (2023). https://doi.org/10.1007/s11130-022-01037-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11130-022-01037-3